Clinical Trials Logo

Graves' Orbitopathy clinical trials

View clinical trials related to Graves' Orbitopathy.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06226545 Recruiting - Eye Diseases Clinical Trials

A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease

Start date: March 5, 2024
Phase: Phase 2
Study type: Interventional

LASN01 is a novel, fully human antibody directed against the human IL-11 receptor being developed for treatment of patients with thyroid eye disease (TED). The primary and secondary objectives of this study are to evaluate the safety, efficacy, and pharmacokinetics of LASN01 administered IV in patients with TED with no prior anti-IGF-1R treatment or in patients with TED who have previously received teprotumumab treatment.

NCT ID: NCT06112340 Recruiting - Eye Diseases Clinical Trials

A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Start date: October 11, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24. These subjects include VGN-TED-301 Week 24 proptosis non-responders or subjects who relapse during the Follow-Up Period of VGN-TED-301.

NCT ID: NCT05276063 Recruiting - Eye Diseases Clinical Trials

A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

LIDS
Start date: July 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).

NCT ID: NCT05199103 Recruiting - Graves Orbitopathy Clinical Trials

Antithymocyte Globulin as a Second Line Therapy in Graves Orbitopathy

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

The overall objective of the study is to evaluate the safety and efficacy of rabbit antithymocyte globulin in the treatment of Graves orbitopathy (GO) after ineffective treatment with moderate-to-high doses of glucocorticoids.

NCT ID: NCT04776993 Recruiting - Graves' Orbitopathy Clinical Trials

A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy

ABLAGO
Start date: March 2, 2023
Phase: Phase 3
Study type: Interventional

Graves' disease (GD) is the most frequent cause of hyperthyroidism in iodine sufficient countries and Graves' orbitopathy (GO) is its most common extrathyroidal manifestation. Restoration and maintenance of euthyroidism are imperative in Graves' disease patients with GO. The main treatment options for Graves' hyperthyroidism are antithyroid drugs, radioactive iodine (RAI), and surgery. Whether one or the other therapy for Graves' hyperthyroidism offers the best protection against GO is not established. The study is aimed at comparing the effects of a conservative approach (antithyroid drugs, ATDs, experimental arm) vs an ablative approach (radioiodine or total thyroidectomy) of thyroid treatment on the overall outcome of GO in patients with GD and moderate-to-severe and active GO treated with intravenous glucocorticoids.